Objective: Endovascular treatment of a significant stenosis in an infrainguinal autologous bypass prevents bypass occlusion and improves bypass patency. Drug-eluting balloons (DEBs) have been proven to possess antirestenotic features in the treatment of femoropopliteal stenoses and occlusions. This study evaluated the effects of DEB angioplasty vs uncoated balloon (UCB) angioplasty to rescue infrainguinal autologous bypass grafts at risk (BAR).
Autologous infrainguinal bypasses are widely used for the treatment of extensive femoropopliteal arterial occlusive disease because they show excellent longterm patency, with reported 5-year patency rates of 60% to 80%. [1] [2] [3] One-third of patients will develop a significant stenosis in the autologous bypass, predominantly in the first year after surgery. 4, 5 An autologous bypass with a significant stenosis is associated with an increased risk for bypass occlusion and is called a bypass at risk (BAR). 4, 6, 7 Duplex ultrasound surveillance is performed to identify autologous bypass stenoses. 8, 9 Early endovascular intervention is the preferred technique to rescue infrainguinal BAR. Although the freedom from recurrent stenosis after percutaneous angioplasty with uncoated balloons (UCBs) is disappointing, repeated endovascular revascularization results in patency rates of >80%.
10,11
In the past decade, drug-eluting balloons (DEBs) have been introduced to improve patency rates. Antiproliferative medication (paclitaxel) on the exterior of the balloon is transferred into the arterial wall using an excipient during inflation to reduce neointimal hyperplasia. 12, 13 Recent meta-analyses of randomized controlled trials comparing treatment of atherosclerotic lesions in femoropopliteal arteries with DEBs and UCBs show a significant reduction of binary restenosis, decreased late lumen loss, and reduction of target lesion revascularization after DEB angioplasty. 14, 15 However, whether endovascular treatment of autologous infrainguinal bypass stenoses with DEBs results in improved outcome compared with UCB angioplasty is still unclear. This study evaluated the effects of DEB angioplasty on significant stenosis in infrainguinal autologous bypass grafts compared with UCB angioplasty.
METHODS
The Maasstad Hospital Institutional Review Board approved the study. The requirement for written patient consent was waived.
Study design. On April 1, 2014, primary treatment of infrainguinal autologous BAR changed from UCB angioplasty to DEB angioplasty in our institution. To obtain a minimal follow-up of 1 year, all consecutive patients with an autologous infrainguinal BAR treated with DEB angioplasty between April 1, 2014, and July 31, 2015, were included. Data on treatment with DEBs were prospectively collected and retrospectively analyzed. These results were compared with a historical cohort of patients with autologous infrainguinal BAR treated with UCB angioplasty, some of which have been published previously. 10 A similar inclusion period length as the DEB cohort of 16 months was chosen for the UCB angioplasty cohort. Therefore, all consecutive patients with an autologous infrainguinal BAR treated with UCB angioplasty from December 1, 2012, to April 1, 2014, were included. Patients that were treated previously with percutaneous transluminal angioplasty (PTA) were all treated before December 1, 2012, ruling out crossover between the two groups.
Indication for endovascular treatment. Patients with peripheral arterial occlusive disease treated with an infrainguinal autologous bypass graft were monitored for at least 1 year according to the guidelines of the Dutch Vascular Society. 16 Duplex ultrasound surveillance was performed at 6 and 12 months after surgery by ultrasound technicians from an accredited vascular laboratory. Thereafter, duplex ultrasound imaging was performed if the patient became symptomatic. A stenosis of >70% was considered a significant stenosis and was defined as a peak systolic velocity of >300 cm/s or a peak systolic velocity ratio >3.0.
Treatment. Patients with BAR were scheduled for digital subtraction angiography. The stenosis or multiple stenoses in the BAR were identified and classified as anastomotic or nonanastomotic. The bypass diameter proximal and distal to the stenosis was measured, and before April 1, 2014, an UCB with a diameter similar to the bypass diameter was used for angioplasty. After April 1, 2014, a Passeo-18 Lux DEB (Biotronik AG, Buelach, Switzerland) was used. All patients received 5000 IU of heparin. All lesions in the DEB group were predilated with an angioplasty balloon 1 mm smaller than the target vessel, and the inflation time was 3 minutes in all patients. No minimal balloon inflation time was indicated in the UCB group.
If a residual stenosis of >30% persisted, prolonged inflation with a UCB was performed. Treatment was considered a technical success if a residual stenosis of <30% was achieved after PTA, with or without prolonged balloon inflation. In case of flow-limiting dissection or residual stenosis of >30%, a self-expanding bare-metal stent was placed. Obstructive lesions in other arterial segments (ie, iliac or tibial) were treated simultaneously with PTA and optional stenting to obtain unimpeded runoff through at least one artery passing the ankle.
Patients received oral anticoagulation therapy for at least 2 years after bypass surgery. 17 Antiplatelet therapy (aspirin) was prescribed for patients who were not eligible for anticoagulation therapy. All patients received a statin as primary cardiovascular protection.
Follow-up. The follow-up protocol was similar in both groups. After endovascular treatment of BAR, patients were routinely monitored in the outpatient clinic. Duplex ultrasound surveillance was performed at 6 and 12 months. In patients with clinical deterioration, duplex ultrasound or direct angiography was performed.
Our institution has adopted an endovascular-first approach for primary and recurrent stenosis. Patients with recurrent significant stenosis in the bypass on duplex ultrasound imaging were rescheduled for digital subtraction angiography, and PTA was performed if a stenosis of >70% was found during angiography. If a bypass occluded during follow-up, thrombolytic therapy or surgical embolectomy was performed. If thrombolytic therapy or surgical embolectomy was not successful or not performed, the bypass was considered failed.
Study end points. Comorbidities and outcomes were in accordance with those proposed by the reporting standards of the Society for Vascular Surgery for endovascular treatment of chronic lower extremity peripheral artery disease. 18 Because primary patency according to the reporting standards was already lost during the first endovascular treatment of BAR, the primary end point of this study was a combined end point of freedom from recurrent stenosis or occlusion after angioplasty of the stenosis in the autologous bypass with a UCB or DEB. Secondary outcomes in this study were primary assisted patency, defined as freedom from any intervention to prevent bypass occlusion; secondary patency, defined as freedom from any intervention to maintain bypass patency after occlusion; major amputation, defined as an amputation above the ankle; and all-cause mortality.
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Statistical methods. Data were collected and stored in on-line case report forms (Castor EDC; Ciwit BV, Amsterdam, The Netherlands). Data were analyzed with SPSS 24 software (IBM, Armonk, NY). All results were analyzed on an as-treated basis. Continuous data are presented as means 6 standard deviation, and categoric data are given as counts with percentages. Means were compared with the independent samples t-test. Differences between counts in groups were compared using the c 2 test. Kaplan-Meier analysis was used to estimate freedom from recurrent stenosis or occlusion, primary assisted patency, and secondary patency. Statistical differences were calculated using log-rank (Mantel-Cox). A P value of <.05 was considered statistically significant.
RESULTS
Patients. The study included 39 endovascularly treated autologous infrainguinal BARs between December 1, 2012, and July 31, 2015; of these, 18 patients were treated with UCB angioplasty and 21 were treated with DEB angioplasty. With the exception of neurologic comorbidity, demographics were evenly distributed between the groups (Table I) , as were bypass characteristics (Table II) .
Procedure. Additional interventions to obtain unimpeded runoff through at least one artery passing the ankle, the location of the stenosis in the bypass, and the number of lesions previously treated with UCBs were evenly distributed between the UCB and DEB groups (Tables II and III) . General anesthesia was used to treat two patients (11%) in the UCB group and four (19%) in the DEB group (P ¼ .53). All other patients were treated under local anesthesia.
Technical success was obtained in all but one patient in the UCB group (P ¼ .27). In this patient, PTA with an UCB resulted in rupture of the bypass, which was successfully treated with a covered self-expandable stent. No other periprocedural complications were observed in the UCB group. One complication occurred in the DEB group (P ¼ .35). A dysrhythmia developed in this patient that needed cardiologic evaluation, but no additional treatment was indicated. The procedure was performed afterward, and the patient fully recovered.
Primary end point. Mean follow-up was 20.8 6 9.7 months in the UCB group and 15.6 6 8.6 months in the DEB group (P ¼ .08). No patients were lost to follow-up. The estimated freedom from recurrent stenosis and the occlusion rate after 1 year was 77.8% 6 9.8% in the UCB group and 80.0% 6 9.0% in the DEB group (P ¼ .76; Fig 1) .
Secondary end points. Primary assisted patency after 1 year was 88.2% 6 7.8% in the UCB group and 95.2% 6 4.6% in the DEB group (P ¼ .47; Fig 2) . Secondary patency after 1 year was 94.1% 6 5.7% in the UCB group and 95.2% 6 4.6% in the DEB group (P ¼ .91; Fig 3) .
Almost half of the patients were asymptomatic before the PTA (Table II) . All patients in the UCB group with intermittent claudication experienced improvement of at least one Rutherford classification. Two patients with critical limb ischemia improved to intermittent claudication, and one patient became asymptomatic. The eight patients in the DEB group with intermittent claudication improved at least one Rutherford classification. One patient with critical limb ischemia became asymptomatic. The bypass in another patient with critical limb ischemia occluded before wound healing occurred.
Recurrent stenosis was observed in four of the bypasses (22.2%) in the UCB group and in four of the bypasses (19.0%) in the DEB group during follow-up (P ¼ .80). In the UCB group, three patients underwent a second PTA with a DEB, and one patient underwent a second PTA with a UCB. The bypasses remained patent afterwards. In the DEB group, two patients underwent a second PTA with a DEB, and one patient underwent three additional PTAs with a DEB to remain patent. One patient underwent a second PTA with a DEB, and a selfexpandable stent was placed because of residual stenosis. The stent occluded 3 days later. Thrombolytic therapy was not successful, and the bypass was considered failed, as mentioned previously.
Bypass occlusion was observed in one patient (5.6%) in the UCB group and in one patient (4.8%) in the DEB group (P ¼ .88). The bypass occlusion in the UCB group occurred after 6 months and was successfully treated with thrombolytic therapy. The bypass occlusion in the DEB group occurred after 3 months and was treated unsuccessfully with thrombolytic therapy, as mentioned previously. No amputations were required. Two patients in the DEB group died within the first year after PTA. One patient died of a malignancy of unknown origin after 
DISCUSSION
This single-center series found DEB angioplasty does not improve freedom from recurrent stenosis or occlusion after 1 year in BARs compared with UCB angioplasty. Primary assisted patency rates and secondary patency rates are also comparable between the two groups. Others have published similar results.
Kitrou et al 19 reported outcomes of 32 patients with failing autologous or synthetic bypasses who underwent DEB angioplasty compared with a historical cohort of 24 patients who were treated with UCB angioplasty. They concluded that DEB angioplasty does not significantly inhibit restenosis or improve freedom from repeat angioplasty. In a retrospective analysis by Linni et al, 20 42 vein bypasses treated with DEB were compared with 41 bypasses treated with UCB. They concluded that treatment of significant infrainguinal vein bypass stenoses with DEB and UCB performed equally with regard to clinical and hemodynamic improvement as well as primary and primary assisted patency rates. A single-arm series of 41 patients with 63 anastomotic or in-graft stenosis of vein or prosthetic bypasses reported cumulative target site primary and secondary patency rates of 70% and 90%, respectively, after 12 months. 21 The freedom from binary restenosis rate (also defined as primary patency in some studies) after treatment with both UCB and DEB has a wide range from <40% up to 88% after 1 year. 10, [19] [20] [21] This may be the result of the heterogeneity of the included lesions, different definitions of stenosis, and the use of different balloons. In contrast to others studies, the current series only included patients with autologous bypasses, and most patients had been treated for a stenosis at the distal anastomosis. Moreover, 17 of 39 patients had been treated previously with UCB angioplasty.
Different outcomes may also be the result of different definitions of a stenosis. In the current study, we defined a significant stenosis as a stenosis of >70%. In other studies, a stenosis of >50% was already considered to be significant, potentially resulting in a decreased freedom from binary restenosis rate. 19, 21 The above-mentioned studies used In.Pact Admiral, In.Pact Pacific, and In.Pact Amphirion (Medtronic, Minneapolis, Minn) DEBs. In the current study, the Passeo-18 Lux DEB was used. All balloons are coated with paclitaxel; however, the excipient to transfer paclitaxel into the vessel wall differs among the balloons. If a therapeutic effect of paclitaxel exists in the treatment of autologous bypass stenosis, the different excipients may have an effect on the restenosis rate. 13, 15 In multiple randomized controlled trials, DEBs have proven to possess antirestenotic features at short-term The optimal treatment for autologous bypass restenosis has yet to be found. The use of cutting balloons is controversial. In a study reporting 161 stenosis in infrainguinal bypasses treated with open surgery (n ¼ 42), PTA (n ¼ 57), or cutting balloons (n ¼ 62), cutting balloon angioplasty was considered a reasonable, safe, and minimally invasive initial treatment for infrainguinal vein graft stenosis in most patients. The authors reported patency rates after treatment with cutting balloons that were comparable to open surgery and superior to PTA. 22 However, in another study reporting 109 cutting balloon angioplasties of infrainguinal vein bypass graft stenoses, the authors stated that cutting balloon angioplasty is technically feasible but associated with a relatively high complication rate and a relatively low short-term patency rate. 23 The effects of drug-eluting stents for the treatment of stenosis in bypasses have only been evaluated in a small series of 11 patients. 24 Expanded polytetrafluoroethylene arteriovenous grafts were created in a porcine model, and drug-eluting stents were implanted over the anastomosis. Intimal hyperplasia was almost completely abolished in this group compared with the unstented and bare-metal stented group. 25 The current study has several limitations. Our treatment regimen of BAR changed from UCBs to DEBs as of April 1, 2014 . Since then, we have prospectively kept a database on these patients. To compare our results, we retrospectively collected a historical cohort treated with UCBs with the exact length of the cohort treated with DEBs. Although our follow-up regimen did not change between the two groups, the collected data are at risk for missing data and selection bias.
Almost half the patients in both groups had been treated previously (Table II) . Although evenly distributed between both groups, analysis in a substantial percentage of the patients was performed for endovascular treatment of a recurrent stenosis.
The small study population is also a limitation and probably responsible for the difference in neurologic comorbidity between the groups. Larger, prospectively managed randomized trials should be performed to fully demonstrate the role of DEBs in the treatment of BAR.
CONCLUSIONS
DEBs and UCBs perform equally in the treatment of significant stenosis in infrainguinal autologous bypasses with regard to freedom from restenosis or bypass occlusion, primary assisted patency, and secondary patency at 1 year. We suggest using a less expensive UCB in the treatment of BAR. 
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